Vera Therapeutics ORIGIN 3 trial to be featured at ASN Kidney Week Oct 17, 2025 09:12AM
Vera Therapeutics Inc. (VERA) Reports Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial Jun 2, 2025 06:31AM
Vera Therapeutics Inc. (VERA) Reports Q4, Provides Business Update Feb 26, 2025 08:25AM
Vera Therapeutics (VERA) Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases Oct 2, 2024 06:31AM
Vera Therapeutics Inc. (VERA) Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results Oct 2, 2024 06:30AM


Jan 25, 2024 06:30AM Vera Therapeutics (VERA) Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Mar 24, 2022 06:30AM Vera Therapeutics Inc. (VERA) Reports Q4 Results